The main objective of the 2022 issues of the What’s Happening section was to encourage an international team of experts to provide the readers with concise reviews of topics of current interest on strategies for risk assessment, predictive diagnosis, and patient management to bring, today, what will be tomorrow’s news.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Transfusion and Apheresis Science
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Dr. Jerard Seghatchian, M.D., Ph.D. A former principal scientific advisor in transfusion and apheresis technologies at NHS BTTS. An International Consultancy with expertise in enhancing innovations in modern precision personalized blood component therapies and training in quality audit/inspection and GMP compliance, traceability, safety, and risk reduction strategies. London, England, UK
Published online: February 28, 2023
Publication stageIn Press Journal Pre-Proof
© 2023 Published by Elsevier Ltd.